Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Abstract Background Methotrexate (MTX) remains the anchor drug in rheumatoid arthritis (RA) treatment, but is poorly tolerated or contraindicated in some patients. There is a wealth of data supporting the use of abatacept in combination with MTX, but data on alternative conventional synthetic diseas...

Descripció completa

Dades bibliogràfiques

Autors principals:	Rieke Alten, Harald Burkhardt, Eugen Feist, Klaus Krüger, Juergen Rech, Andrea Rubbert-Roth, Reinhard E. Voll, Yedid Elbez, Christiane Rauch
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2018-01-01
Col·lecció:	Arthritis Research & Therapy
Matèries:	Abatacept Conventional synthetic disease-modifying antirheumatic drug Azathioprine Hydroxychloroquine Leflunomide Methotrexate
Accés en línia:	http://link.springer.com/article/10.1186/s13075-017-1488-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!